GRAIL Inc. (NASDAQ: GRAL) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $4.8B. The Maz Rating grades it against the other companies in its sector.
GRAIL Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $105.88, GRAIL Inc. trades at 28.6x sales and 2.0x book value. Over the last twelve months it generated about $166M of revenue and a net loss of $427M. It runs a gross margin of -13.4%, an operating margin of -347.3% and a net margin of -243.8%. It shows return on equity of -16.1%, return on invested capital of -16.2% and a free cash flow yield of -6.5%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 8.93. Over the past 52 weeks the share price ranged from $41.50 to $166.48, with a beta of 3.25.
GRAIL Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 5 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, GRAIL Inc. (GRAL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.1% / 30% · Interest income / Revenue 20.9% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.1% / 33% · Receivables / Mkt Cap (36m) 0.39% / 49% · Interest income / Revenue 20.9% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.1% / 33.33% · Receivables / Mkt Cap (24m) 0.39% / 33.33% · Interest income / Revenue 20.9% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.85% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 29.9% / 33.33% · Receivables / Avg Assets (4Q) 0.68% / 33.33% · Interest income / Revenue 20.9% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 28.9% / 33.33% · (Cash+Recv) / Total Assets 29.6% / 33.33% · Interest income / Revenue 20.9% / 5% | Fail |
No. As of September 2026, GRAIL Inc. (GRAL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. GRAIL Inc. is over the AAOIFI limit on Interest income / Revenue.
About 20.9% of each dividend: GRAIL Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.